Fed Sinks Markets
Health Care: Drugs
XOMA Corp (XOMA: NASDAQ)
$3.64 -0.20 | -5.21%
06/19/13 - 04:00 PM ET
Company Income Statement
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Sales | 33.78M | 58.20M | 33.64M | 98.43M |
| Cost of Sales | 143.00K | 0.00 | 0.00 | 0.00 |
| Gross Operating Profit | 33.64M | 58.20M | 33.64M | 98.43M |
| Selling, General, and Administrative Expenses | 16.86M | 24.01M | 23.25M | 23.74M |
| Research & Development | 68.32M | 68.14M | 77.41M | 58.13M |
| Operating Income before D & A (EBITDA) | -51.55M | -33.96M | -67.02M | 16.56M |
| Depreciation & Amortization | 6.08M | 6.72M | 5.72M | 6.83M |
| Interest Income | 0.00 | 0.00 | 16.00K | 49.00K |
| Other Income - Net | -10.13M | 3.69M | -1.26M | -1.84M |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -72.83M | -36.98M | -74.06M | 4.33M |
| Interest Expense | 4.39M | 2.46M | 385.00K | 4.89M |
| Pre-Tax Income | -77.22M | -39.44M | -74.45M | -554.00K |
| Income Taxes | -74.00K | 15.00K | 27.00K | 5.73M |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -71.06M | -32.74M | -68.76M | 550.00K |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -71.06M | -32.74M | -68.76M | 550.00K |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -71.06M | -32.74M | -68.76M | 550.00K |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-65.99M | -32.74M | -68.67M | 4.15M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -71.06M | -32.74M | -68.76M | 550.00K |
| Basic EPS from Continuing Ops. | -1.10 | -1.04 | -3.69 | 0.00 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -1.10 | -1.04 | -3.69 | 0.00 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -1.10 | -1.04 | -3.69 | 0.00 |
| Basic Normalized Net Income/Share | -1.02 | -1.04 | -3.69 | n.a. |
| EPS fr Continuing Ops. | -1.10 | -1.04 | -3.69 | 0.00 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -1.10 | -1.04 | -3.69 | 0.00 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -1.10 | -1.04 | -3.69 | 0.00 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-1.02 | -1.04 | -3.69 | n.a. |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with XOMA
- Portfolio NameUser Type
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks With Big Insider Buy...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- Usersuresh45
- Userdd
- ContributorStocks Under-$10 Setting Up...
- Userconsidering
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
Latest XOMA Headlines from TheStreet
- XOMA Announces Clinical Study Investigating Gevokizumab In Patients With Non-Infectious Anterior Scleritis Has Opened For Enrollment At The National Eye Institute 04.10.13 | 08:04 am
- 8 Stocks Under $5 Seeing Institutional And Insider Buying 04.02.13 | 03:04 pm
- 7 Biotechnology Stocks With Insider Buying Activity 03.20.13 | 10:03 am
- XOMA Appoints Tom Klein To Newly Created Position Of Chief Commercial Officer 03.18.13 | 01:03 pm
- EZChip: My Struggling Core Holding May See Better Days 03.16.13 | 07:03 am
- XOMA Reports 2012 Operational Highlights And Fourth Quarter And Full-Year Financial Results 03.12.13 | 04:03 pm
- XOMA Announces Fourth Quarter And Full-Year Financial Results Conference Call 03.04.13 | 01:03 pm
- 5 Stocks Under $10 Set to Soar 02.28.13 | 01:02 pm
- XOMA To Present At Upcoming Investor Conferences 02.21.13 | 09:02 am
- XOMA Announces Encouraging Interim Results From Gevokizumab Phase 2 Study For Moderate To Severe Acne Vulgaris 01.07.13 | 08:01 am
Press Releases for XOMA
- CMC Biologics Acquires XOMA's Bay Area Manufacturing Facility - PR Newswire 07.31.12 | 08:07 am
Partner Headlines for XOMA
- Positive Data on XOMA Candidate - Analyst Blog - Zacks 11.26.12 | 06:11 pm
- UPDATE: Credit Suisse Initiates XOMA Corporation at Outperform on Upside Potential - Benzinga 11.13.12 | 01:11 pm
- XOMA Announces Servier Has Initiated Phase 3 Gevokizumab Trial in Patients With Behcet's Uveitis - Benzinga 09.27.12 | 01:09 pm
- Orphan Status for XOMA's Candidate - Analyst Blog - NASDAQ 08.23.12 | 07:08 pm
- Loss at XOMA Wider Than Expected - Analyst Blog - Zacks 03.20.12 | 10:03 am
- Noteworthy Institutional 5% Ownership Filings Last Week - Seeking Alpha 03.19.12 | 09:03 am
- Xoma's New Plans Bring Hesitant Hope - Seeking Alpha 01.25.12 | 09:01 am
- XOMA Will Move Its Corporate Domicile to Delaware - Benzinga 12.30.11 | 04:12 pm
- XOMA CEO Engle Resigns - Benzinga 08.31.11 | 04:08 pm
- 15 Stocks Posting Big Jumps This Week - Seeking Alpha 06.30.11 | 08:06 am
